Shares in Stratagene dropped to a 52-week low of $5.40 late last week, a few days after the firm posted a second-quarter loss. Despite the announcement earlier this week of a collaboration with Merck unit Rosetta Inpharmatics (see related article), Stratagene’s shares regained little ground, closing Tuesday at $5.49, down 19.7 percent for the tracking period.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.